Coronavirus in HIP Fractures CHIP 2: Is Vitamin D Deficiency Associated with Increased Mortality from COVID-19 Infections in A Hip Fracture Population?



Abstract Views
884

Downloads
452

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Nov 29, 2021
Published Dec 29, 2021
10.24018/ejmed.2021.3.6.1159

Abstract viewed = 884 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Purpose: There is controversy as to whether vitamin D deficiency is associated with increased mortality from coronavirus infection. The aim of the study was to assess the relationship between vitamin D levels and 30-day mortality in hip fracture patients co-infected with COVID-19.

Methods: This was a national observational audit conducted between 23 March 2020 (start of UK lockdown) and 31st December 2020. The cohort consisted of patients aged >60 years presenting with a hip fracture. Patients were included if they had a vitamin D level done during the admission episode, diagnosis of COVID-19 infection via a viral reverse transcriptase PCR swab, and a hip fracture. There were 517 patients included in the study from 43 different hospital trusts. The primary outcome measure was 30-day mortality. Secondary outcomes were the percentage of patients who had vitamin D deficiency, the percentage of patients who were prescribed Vitamin D, and the impact of vitamin D prescribing on mortality

Results: Vitamin D deficiency was not associated with a higher 30-day mortality. Low serum vitamin D was observed in 56% of the patients on admission. Vitamin D was prescribed prior to admission in 28% and during admission in a further 49%. Pre-hospital vitamin D therapy reduced the chance of vitamin D deficiency. Starting vitamin D before or on admission did not affect the mortality rates.

Conclusion: Vitamin D deficiency was common, but not associated with a higher 30-day mortality in the hip fracture population co-infected with COVID-19.

Keywords: COVID-19, hip fracture, SARS-COV-2, vitamin D

Downloads

Download data is not yet available.

References

  1. WHO Coronavirus (COVID-19) Dashboard. [Internet] 2020. [Accessed on March 27, 2021]. Available from: http://covid19.who.int
     Google Scholar
  2. Boban M. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract. 2021; 75(4): e13868.
    DOI  |   Google Scholar
  3. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 2020; 8(7): 570.
    DOI  |   Google Scholar
  4. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020; 32(7): 1195-1198.
    DOI  |   Google Scholar
  5. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open. 2020; 3(9): e2019722.
    DOI  |   Google Scholar
  6. Craveiro V, Cabral M, Araújo J, Falcão H, Guimarães JT, Ramos E. Association of Serum 25-Hydroxyvitamin D Concentration with Pulmonary Function in Young Adults. Nutrients. 2018; 10(11): 1728.
    DOI  |   Google Scholar
  7. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009; 169(4): 384-90.
    DOI  |   Google Scholar
  8. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017; 356: i6583.
    DOI  |   Google Scholar
  9. Laird E, Rhodes J, Kenny RA. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19. Ir Med J. 2020; 113(5): 81.
     Google Scholar
  10. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol (Oxf). 2020; 93(4): 508-511.
    DOI  |   Google Scholar
  11. Mahmood A, Rashid F, Limb R, Cash T, Nagy MT, Zreik N, et al. Coronavirus infection in hip fractures (CHIP) study. Bone Joint J. 2021; 103-B(4): 782-787.
    DOI  |   Google Scholar
  12. The Caldicott Report. IHRIM. 1999 Jun; 40(2): 17-9
    DOI  |   Google Scholar
  13. Marufu TC, White SM, Griffiths R, Moonesinghe SR, Moppett IK. Prediction of 30-day mortality after hip fracture surgery by the Nottingham Hip Fracture Score and the Surgical Outcome Risk Tool. Anaesthesia. 2016; 71(5): 515-21.
    DOI  |   Google Scholar
  14. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020; 203: 10575
    DOI  |   Google Scholar
  15. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021; 325(11): 1053-1060.
    DOI  |   Google Scholar
  16. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One. 2020; 15(9): e0239252.
    DOI  |   Google Scholar
  17. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van den Abbeele K et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J. 2021; 97(1149): 442-447.
    DOI  |   Google Scholar
  18. Hastie CE, Pell JP, Sattar N. Vitamin D and COVID-19 infection and mortality in UK Biobank. Eur J Nutr. 2021; 60(1): 545-548.
    DOI  |   Google Scholar
  19. Pizzini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, et al. Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry. Nutrients. 2020; 12(9): 2775.
    DOI  |   Google Scholar
  20. Liu N, Sun J, Wang X, Zhang T, Zhao M, Li H. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2021; 104: 58-64.
    DOI  |   Google Scholar
  21. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020; 12(4): 988.
    DOI  |   Google Scholar
  22. McCartney DM, Byrne DG. Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19. Ir Med J. 2020; 113(4): 58.
     Google Scholar
  23. NICE guideline [NG187] COVID-19 rapid guideline: vitamin D. 2020. [Accessed on March 27, 2021] Available from: https://.nice.org.uk/guidance/NG187
     Google Scholar
  24. NICE>CKS>Health Topics A to Z >Vitamin D deficiency in adults - treatment and prevention [Accessed 27th March 2021].Available from: http://cks.nice.org.uk/topics/vitamin-d-deficiency-in-adults/management
     Google Scholar